Email nurture for Series B companies: scaling without breaking for healthcare and life sciences in the APAC region
How Series B companies scale email nurture across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the APAC region.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install email nurture has to be shaped to that reality from day one.
Series B is the stress test for email nurture. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.
The Series B move is to separate the model owner from the operators. One senior human owns strategy, lead-to-opportunity conversion by cohort, and the weekly review; a small team runs the machine.
Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Email nurture is only useful here when it is pointed at both constraints at once.
Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.
The Series B failure mode of email nurture is generic drips that read like a newsletter, amplified by headcount. Fix the root cause; do not paper over it with more people.
Compensation begins to matter now. Pay operators on lead-to-opportunity conversion by cohort outcomes, not on effort. Effort-based comp at Series B produces theatre.
A well-run email nurture function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.
Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing email nurture deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Lifecycle · healthcare · APAC — answered
- Does email nurture work for healthcare and life sciences in the APAC region?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market. The healthcare teams that install this get past procurement instead of dying in it.
- How does email nurture change at Series B?
- Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
- When should we expand to a second region?
- After the first region delivers two straight quarters of defensible lead-to-opportunity conversion by cohort.
- What compensation model works for email nurture operators at Series B?
- Outcome-linked on lead-to-opportunity conversion by cohort, not activity-based.
- What is the Series B stress point?
- Generic drips that read like a newsletter, amplified by headcount. Fix the root, not the symptom.
- What is the APAC-specific pitfall when running email nurture for healthcare?
- Importing a playbook that was built for another market. In the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market — the install has to reflect that.
Growth Broker editorial
Filed under lifecycle · healthcare · apac